Active substance: Sulbutiamine
ATC code: A11da02
CCF: The Drug, used in asthenic conditions
ICD-10 codes (testimony): (F) 48.0
FSC Code: 16.11
Manufacturer: Les Laboratoires Servier (France)
DRUG FORM, COMPOSITION AND PACKAGING
Tablets, film-coated tablets Orange, round, Lenticular, can a small different surface (by glâncevosti), staining and slight inclusions.
Auxiliary substances: corn starch, starch paste dried, dextrose anhydrous, lactose monohydrate, magnesium stearate, TALC, sodium hydrogen, sodium carboxymethylcellulose, White beeswax, titanium dioxide (E171), ethyl cellulose, yellow dye (Sunset yellow FCF, E110), glycerol monooleat, polysorbate 80, povidone, sucrose, anhydrous colloidal silica.
10 PCs. — blisters (2) — packs of cardboard.
15 PCs. — blisters (4) — packs of cardboard.
Synthetic compound, close to the structure of thiamine. The molecule sul′butiamina has open tiazolny cycle, additional disulfidnuu and lipophilic stream. Due to such modification is rapidly absorbed from the digestive tract and easily permeates through GEB.
Unlike the thiamine, is able to accumulate in the cells retikuliarna formations, the hippocampus and dentate gyrus, as well as in the cells of Purkinje fibers and clubockah granular layer of cerebellar cortex.
Against the backdrop of the admission Èneriona is improved coordination and increased resistance to physical stress, resistance patterns of the cerebral cortex to the repeating of hypoxia.
After intake of rapidly absorbed from the digestive tract sulbutiamine, (C) max in plasma achieved through 1-2 h.
T1/2 is about 5 h. Return with urine.
-symptomatic treatment of functional asthenia.
Adults the drug is prescribed a daily dose of 400-600 mg500ml (2-3 table.) in 2 reception.
The tablets should be taken inside for breakfast and lunch.
The duration of treatment should not exceed 4 weeks.
Of the central nervous system: tremor, headache, excitation, general malaise.
On the part of the digestive system: neuralgia.
Allergic reactions: possible skin manifestations.
-hypersensitivity to the preparation components.
PREGNANCY AND LACTATION
According to the results of clinical trials of the drug does not affect fetal development. However,, the lack of sufficient clinical data does not recommended to appoint Ènerion in pregnancy and lactation (breastfeeding).
Not recommended to appoint Ènerion patients with lactase deficiency, galaktozemiej or glûkoznoj/galaktoznoj malabsorption syndrome due to, that the product is lactose monohydrate.
Use in Pediatrics
The drug is not recommended to appoint children and adolescents under the age of 18 years due to the lack of clinical data.
Impact on the ability to drive vehicles and management mechanisms
The drug does not affect the ability to drive vehicles and management mechanisms.
Symptoms: possible excited state phenomena of euphoria and tremor limbs.
Treatment: symptoms quickly disappear on its own and does not require special treatment.
PRESCRIBED DRUG INTERACTION
Prescribed drug interaction is missing.
PHARMACY PURCHASING TERMS
The drug is available by prescription.
The drug should be kept out of the reach of children at a temperature of no higher than 25° c. Shelf life — 3 of the year.